Telatinib mesylate

• CAT Number: I017259
• CAS Number: 332013-26-0
• Molecular Formula: C₂₁H₂₀ClN₅O₆S
• Molecular Weight: 505.93
• Purity: ≥95%
• Target: VEGFR
• IUPAC Name: 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide;methanesulfonic acid
• InChI: InChI=1S/C20H16ClN5O3.CH4O3S/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14;1-5(2,3)4/h2-10H,11H2,1H3,(H,22,27)(H,24,25);1H3,(H,2,3,4)
• InChIKey: LCMLACPWPXITHP-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl.CS(=O)(=O)O

Telatinib Mesylate(CAT: I017259) is a potent small-molecule inhibitor targeting vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3), platelet-derived growth factor receptor β (PDGFR-β), and c-Kit. By blocking these receptor tyrosine kinases, Telatinib disrupts angiogenesis and tumor vascularization, inhibiting tumor growth and metastasis. This mechanism makes it highly relevant in the Oncology field, especially in cancer research focused on anti-angiogenic therapies. Telatinib Mesylate is instrumental in studying solid tumors and hematologic malignancies, providing a promising approach for developing targeted cancer treatments by suppressing blood vessel formation essential for tumor survival and progression.